Eli Lilly

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

News

NICE changes its mind on Lilly's Mounjaro for diabetes

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiven

News

Amazon Pharmacy rolls out insulin discount coupons

Amazon Pharmacy has said that it will automatically apply manufacturer coupons on over 15 insulin and diabetes care products from manufacturers like Novo Nordisk, Eli Lill

News

Regeneron dials up in gene therapy with Decibel deal

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a

News

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

CHMP backs Almirall’s eczema therapy lebrikizumab

NICE changes its mind on Lilly's Mounjaro for diabetes

Amazon Pharmacy rolls out insulin discount coupons

Regeneron dials up in gene therapy with Decibel deal

Advantage Novo Nordisk in battle of weight-loss drugs

Nektar says Lilly got it wrong on eczema drug rezpeg

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks